Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Consensus Target Price of $22.43

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $22.00.

A number of research analysts have commented on the stock. Leerink Partners increased their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the company an “outperform” rating in a research note on Friday. Wall Street Zen lowered shares of Arcturus Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday, July 17th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Finally, Roth Capital restated a “buy” rating and issued a $41.00 target price on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently bought and sold shares of ARCT. Sumitomo Mitsui Trust Group Inc. raised its stake in Arcturus Therapeutics by 12.9% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,288,935 shares of the biotechnology company’s stock valued at $17,671,000 after buying an additional 262,347 shares in the last quarter. Amova Asset Management Americas Inc. lifted its holdings in Arcturus Therapeutics by 12.9% during the 1st quarter. Amova Asset Management Americas Inc. now owns 2,288,935 shares of the biotechnology company’s stock worth $17,648,000 after buying an additional 262,347 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Arcturus Therapeutics in the 2nd quarter worth approximately $17,566,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Arcturus Therapeutics by 23.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 346,207 shares of the biotechnology company’s stock worth $2,327,000 after acquiring an additional 66,528 shares in the last quarter. Finally, Heartland Advisors Inc. acquired a new position in shares of Arcturus Therapeutics in the 1st quarter worth approximately $1,976,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Down 8.2%

Shares of ARCT opened at $12.61 on Tuesday. The firm has a market cap of $358.41 million, a price-to-earnings ratio of -3.81 and a beta of 2.48. The business’s 50 day moving average is $12.88 and its two-hundred day moving average is $9.35. Arcturus Therapeutics has a 52-week low of $5.50 and a 52-week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.16. The business had revenue of $2.96 million during the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, equities analysts expect that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need.